Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$202.78 USD

202.78
679,575

+1.10 (0.55%)

Updated Nov 6, 2024 10:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Merck (MRK) Keytruda Betters Survival in Adjuvant Lung Cancer

Merck's (MRK) phase III study evaluating Keytruda for adjuvant stage IB-IIIA non-small cell lung cancer (NSCLC) meets one of its dual primary endpoints of disease-free survival (DFS).

Pfizer (PFE) Partners Beam Therapeutics for Rare Disease Drugs

Pfizer (PFE) collaborates with Beam Therapeutics (BEAM) to advance the next generation of gene-editing therapies.

AbbVie (ABBV) Gains As Market Dips: What You Should Know

AbbVie (ABBV) closed at $136.39 in the latest trading session, marking a +1.12% move from the prior day.

AstraZeneca (AZN) Inks Deal to Develop ATTR-CM Candidate

AstraZeneca (AZN) inks collaboration and license agreement with Neurimmune AG to develop/commercialize the latter's NI006 for treating transthyretin amyloid cardiomyopathy.

Sanofi (SNY) Inks Deal to Develop AI-Driven Precision Medicines

Sanofi (SNY) signs a collaboration agreement with Exscientia to develop precision-engineered medicines in oncology and immunology using the latter's AI-driven platform.

The Zacks Analyst Blog Highlights: Pfizer, AbbVie, Eli Lilly and J&J

Pfizer, AbbVie, Eli Lilly and J&J are included in this analyst blog.

AbbVie (ABBV) Seeks Rinvoq Nod for Non-Radiographic AS

AbbVie's (ABBV) application seeking approval of Rinvoq for nr-axSpA was based on data from the phase III SELECT-AXIS 2 (Study 2) study.

Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt

Aligos Therapeutics' (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.

Lilly (LLY) Inks Deal for Multiple Neurologic Indications

Eli Lilly (LLY) partners with Entos Pharmaceuticals to expand its pipeline in multiple neurologic indications.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to PFE Booster for Age 12-15, Breakthrough Tag to ABBV Drug

FDA authorizes Pfizer's (PFE) booster shot for adolescents 12 -15 years of age and grants Breakthrough Therapy tag to AbbVie's (ABBV) lung cancer candidate.

Zacks Investment Ideas feature highlights: AbbVie, Inc. and Pfizer Inc

AbbVie, Inc. and Pfizer Inc are highlighted in this investment idea article.

4 Reasons Why You Should Add AbbVie (ABBV) to Your Portfolio

AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

Mark Vickery headshot

Top Analyst Reports for JPMorgan, Toyota & Netflix

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Toyota Motor Corp. (TM) and Netflix, Inc. (NFLX).

AbbVie (ABBV) is an Incredible Growth Stock: 3 Reasons Why

AbbVie (ABBV) is well positioned to outperform the market, as it exhibits above-average growth in financials.

AbbVie (ABBV) Gets FDA Breakthrough Tag for Lung Cancer Drug

AbbVie's (ABBV) Breakthrough Therapy Designation for Teliso-V is based on data from the phase II LUMINOSITY study.

Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?

Here is how AbbVie (ABBV) and Allakos Inc. (ALLK) have performed compared to their sector so far this year.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $135.42, marking a +0.01% move from the previous day.

AbbVie (ABBV) Stock Moves -0.01%: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $134.39, moving -0.01% from the previous trading session.

Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?

Smart Beta ETF report for DHS

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $132.05, moving +1.62% from the previous trading session.

Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?

Style Box ETF report for DHS

Pfizer (PFE) COVID Pill Paxlovid Gets CHMP Support in Europe

The CHMP supports the use of Pfizer's (PFE) oral COVID-19 drug, Paxlovid, to treat high-risk patients even though it has not received conditional authorization from the European Commission.

Kinjel Shah headshot

Pharma Stock Roundup: PFE Announces Arena Buyout, LLY Ups 2021 View & More

Pfizer (PFE) offers to buy Arena Pharmaceuticals. Lilly (LLY) raises 2021 profit and sales outlook.

AbbVie (ABBV) Gains As Market Dips: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $131.78, moving +1.19% from the previous trading session.